BioCentury | Dec 8, 2008
Finance

Ebb & Flow

With capital markets tight, biotech companies are looking for non-dilutive ways to guarantee access to new funds should they need them. Last week, Micromet (NASDAQ:MITI) and Newron (SWX:NWRN) both secured equity agreements that provide them...
BioCentury | Dec 8, 2008
Company News

Omrix, J&J deal

Johnson & Johnson will acquire its partner Omrix for $25 per share in cash, or about $438 million based on 17.5 million fully diluted shares outstanding. The price is an 18% premium to Omrix's close...
BioCentury | Nov 25, 2008
Top Story

J&J to acquire Omrix

Johnson & Johnson (NYSE:JNJ) said it will acquire Omrix (NASDAQ:OMRI) for $25 per share in cash, or $438 million. The price is an 18% premium to Omrix's close of $21.16 on Friday, before the deal...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

Investors lopped off one-third of PDL Biopharma 's value last Wednesday after the company announced late Tuesday that it was taking itself off the auction block after failing to receive any firm offers to purchase...
BioCentury | Jan 7, 2008
Finance

New products to watch

New products to watch Company Product Indication Location Acambis (LSE:ACM) ACAM2000 Prevent smallpox in subjects at high risk of exposure U.S. Actelion (SWX:ATLN) Tracleer bosentan Reduce the number of new digital ulcers in patients with...
BioCentury | Oct 1, 2007
Finance

3Q approvals

3Q approvals 3Q approvals Selected third quarter product approvals Company Approval Acambis (LSE:ACM) FDA approves ACAM2000 smallpox vaccine for use in subjects at high risk of exposure Anesiva (ANSV) FDA approves Zingo needle-free injection of...
BioCentury | Sep 17, 2007
Clinical News

Evithrom thrombin: Additional Phase III data

Additional data from a Phase III trial in 305 patients showed that 3.3% of patients who received Evithrom human thrombin developed an anti-thrombin antibody compared with 12.7% of patients who received bovine thrombin (p=0.01). Data...
BioCentury | Sep 17, 2007
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/14 cls Alnylam (ALNY) Cantor Fitzgerald Pamela Bassett Upgrade Buy (from hold) 4% $27.99 Bassett raised her target to $32...
BioCentury | Sep 3, 2007
Clinical News

Evithrom thrombin regulatory update

FDA approved a BLA for Evithrom human thrombin, a topical human plasma-derived concentrate of stabilized thrombin for general hemostasis in surgery. OMRI manufactures Evithrom and will receive royalties from Ethicon Inc., a subsidiary of Johnson...
BioCentury | Sep 3, 2007
Finance

Ebb & Flow

Xoma (XOMA) managed to more than double its cash via last week's licensing deal with Pfizer (PFE). Investors welcomed the news, boosting the shares $0.47 (20%) to $2.77 and a market cap of $365 million....
Items per page:
1 - 10 of 11